David DobnikScientific Associate at National Institute of Biology, Slovenia
David Dobnik, PhD in biotechnology, has been working at National Institute of Biology for thirteen years. His main focus area is development of new nucleic acid detection/quantification approaches.
From 2016 he has been closely working with companies in the field of gene therapy (including but not limited to AveXis (now Novartis Gene Therapies) and Axovant Gene Therapies) to develop and apply methods for precise quantification of viral vectors (e.g. ddPCR, qPCR), observation of viral particles (electron microscopy), and for identification and quantification of impurities (e.g. nucleic acids by high-throughput sequencing (HTS/NGS) or PCR-based methods, and other by electron microscopy). This way, National Institute of Biology enables efficient development of up- and downstream processes of therapeutic viruses production and performs tech transfer of new analytical methods.”